Form 4: Eli Lilly Director J. Erik Fyrwald Acquires Shares Through Deferred Compensation Plan

Eli Lilly & Co. Director J. Erik Fyrwald acquired 13.011 shares of common stock valued at $762.18 per share, as part of a deferred compensation plan.

Summary

• J. Erik Fyrwald, a Director at Eli Lilly & Co. (LLY), acquired 13.011 shares of common stock.
• The transaction occurred on July 21, 2025, at a price of $762.18 per share.
• These shares were acquired in lieu of cash compensation and deferred as stock units under the Lilly Directors' Deferral Plan.
• The stock units will be settled in shares of common stock following Fyrwald's separation from service.
• Following this transaction, J. Erik Fyrwald directly beneficially owns 73,012.779 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, particularly as part of a deferred compensation plan, is generally a positive signal as it increases insider ownership and aligns interests with shareholders. It's a routine compensation event, not a discretionary purchase, hence not a strong 'buy' signal, but still positive for alignment.

Positives

• Director J. Erik Fyrwald increased his direct beneficial ownership in Eli Lilly & Co. by acquiring 13.011 shares.
• The acquisition is part of a deferred compensation plan, indicating alignment of director incentives with shareholder interests.

Future Outlook

The acquired shares, deferred as stock units, will be settled in common stock following the reporting person's separation from service, indicating a long-term holding strategy for this portion of compensation.

Industry Context

This transaction reflects a common practice in the pharmaceutical industry where executive and director compensation often includes equity components, aligning leadership interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The practice of deferring cash compensation into stock units is a standard corporate governance practice across various industries, including pharmaceuticals, to align director incentives with long-term shareholder value.
• Many large pharmaceutical companies, such as Pfizer, Merck, and Johnson & Johnson, utilize similar equity-based compensation plans for their directors and executives.
• The specific value of shares acquired is proportional to the director's compensation structure at Eli Lilly, which is competitive within the top-tier pharmaceutical sector.

Corporate Governance

Related Party Transactions

• The acquisition of shares by a director (J. Erik Fyrwald) from the company (Eli Lilly & Co.) as part of a compensation plan constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively as it aligns director interests with long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The acquired stock units will be settled in shares of common stock following the reporting person's separation from service.

Key Dates

Recommendation

This Form 4 reports a routine acquisition of shares by a director as part of a deferred compensation plan. While it indicates continued alignment of interests, it is not a discretionary purchase based on new material information that would warrant a change in investment recommendation. The transaction is expected and part of standard corporate compensation practices.

Keywords

Eli Lilly, LLY, J. Erik Fyrwald, Director, Insider Transaction, Form 4, Stock Acquisition, Deferred Compensation, Beneficial Ownership, Pharmaceuticals